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ABSTRACT: 41 
 42 
A new anhydrous polymorph of the free base of sildenafil and two solvates (acetonitrile and 43 
propanenitrile) have been discovered and fully characterized. The new polymorph can be considered a 44 
desolvate of the acetonitrile solvate and is related to the most stable form I by morphotropism. The new 45 
polymorph can only be obtained by desolvation of the acetonitrile solvate. Thus, this study is a new 46 
example of the importance of this multicomponent family of solid forms in the discovery of new 47 
polymorphs of active pharmaceutical ingredients. 48 
 49 
 50 
 51 
 52 
 53 
54 
1. INTRODUCTION 55 
 56 
Active pharmaceutical ingredients (APIs) can exist in addition to polymorphs as solvates, a phenomenon 57 
known as pseudopolymorphism.1 Since APIs are small molecular weight compounds, they tend to form 58 
solvates and hydrates where solvent molecules are an integral part of the solid form structure. In 59 
particular, water molecules can occupy isolated sites (stoichiometric hydrates) or channels 60 
(stoichiometric and nonstoichiometric hydrates).2 Frequently, the removal of water molecules produces 61 
the collapse of the crystal network with the result of an amorphous3 form or an anhydrous 62 
polymorph.4,5 63 
Although it has been suggested that 33% of organic compounds can form hydrates but only 10% of them 64 
can form solvates,6 the formation of solvates can have important consequences during the development 65 
of an API because they can affect their physicochemical properties such as stability or solubility in 66 
relation to the anhydrous form.7,8 The Cambridge Structural Database (CSD) has been searched in 67 
order to study the frequency of solvate formation, and more than 300 different solvent molecules were 68 
identified to form a solvate.9 Moreover, hydrate formation in organic compounds and the important 69 
factors determining the high frequency of hydrates have been studied by analyzing the CSD,10 and 70 
statistical models for the prediction of hydrate and solvate formation have been developed.11 71 
API solvates are generally prepared by recrystallization, but hydrates may also appear during 72 
formulation of a drug while being exposed to air. But while pharmaceutical hydrates are viable forms for 73 
drug products because there is no safety concern about water as a crystal adduct, solvates are rarely 74 
formulated because of safety concerns due to solvent toxicity.12,13 However, the phenomenon of 75 
pseudopolymorphism can have a significant impact in the development of a pharmaceutical drug since 76 
the pharmaceutical drugs are usually in contact with organic solvent during the purification and 77 
processing stages.14 Particularly relevant is the case of sulfathiazole,15 which forms over 100 solvates. 78 
Usually solvate structures collapse immediately after the removal of the solvent; however, in some cases 79 
isomorphic desolvates are formed when the solvent molecules are removed without the collapse of the 80 
crystal network and retain most of the packing issues of the parent solvate.16 Thus, isomorphic 81 
desolvates can be regarded as different polymorphs but constitute a specific category of solid forms 82 
since they can only be formed by desolvation and stabilized in the absence of solvent molecules.17 The 83 
presence of voids in the desolvate structure is related to its usual tendency to be hygroscopic18,19 and to 84 
a lower stability based on a reduced packing efficiency.20 In some cases, the desolvation produces very 85 
small crystallites that although crystalline at a local level give poorly defined powder X-ray diffraction 86 
(PXRD) patterns, which hinder their characterization.21 Although hydrates and solvates constitute a 87 
topic of continuous research interest in the pharmaceutical industry, isomorphic desolvates have been 88 
scarcely explored in the crystal engineering field to date.22 Thus, in this paper we report a new 89 
isomorphic desolvate of the free base of sildenafil which is morphotropically related to the known 90 
anhydrous form I. The study has been completed with the full characterization of new acetonitrile and 91 
propanenitrile solvates of sildenafil, which are key to understanding the role of the solvent in the 92 
discovery of the new polymorph of sildenafil. 93 
 94 
 95 
  96 
2. MATERIALS AND METHODS 97 
 98 
2.1. Materials. Sildenafil used in this study was of reagent grade and used as received from Polpharma 99 
(form I). Anhydrous form II has been obtained by slurring sildenafil (form I) in ACN followed by fast 100 
drying under a vacuum (30 min) at 25 °C. ACN solvate (form ACNI) has been obtained by slow 101 
crystallization in ACN after 37 days at 25 °C. ACN solvate (form ACNII) has been obtained after 102 
keeping sildenafil (form I) in ACN atmosphere for 2 weeks. Propanenitrile solvate has been obtained by 103 
slow crystallization in propanenitrile after 1 day at 25 °C. 104 
2.2. Methods. 2.2.1. X-ray Crystallographic Analysis. Single crystal X-ray diffraction intensity data of 105 
sildenafil form I and acetonitrile solvate form ACNI were collected using a D8 Venture system equipped 106 
with a multilayer monochromator and a Mo microfocus (λ = 0.71073 Å). Frames were integrated with 107 
the Bruker SAINT software package using a SAINT algorithm. Data were corrected for absorption 108 
effects using the multiscan method (SADABS).23 The structure was solved and refined using the Bruker 109 
SHELXTL Software Package, a computer program for automatic solution of crystal structures and 110 
refined by full-matrix least-squares method with ShelXle Version 4.8.0, a Qt graphical user interface for 111 
SHELXL computer program.24 112 
Powder X-ray diffraction pattern of form II was obtained on a PANalytical X’Pert PRO MPD 113 
diffractometer in transmission configuration using Cu Kα1+2 radiation (λ = 1.5406 Å) with a focusing 114 
elliptic mirror and a PIXcel detector working at a maximum detector’s active length of 3.347°. 115 
Configuration of convergent beam with a focalizing mirror and a transmission geometry with flat 116 
sample sandwiched between low absorbing films measuring from 2 to 80° in 2θ, with a step size of 117 
0.013° and a total measuring time of 2 h. The powder diffractogram data were perfectly indexed to a 118 
orthorhombic cell of about 4954 Å3 by means of Dicvol04,25 and the space group perfectly was 119 
determined to be Pccn from the systematic absences. With one independent molecule of sildenafil in the 120 
asymmetric unit, Z = 8, the crystal structure was determined by direct space methodologies starting from 121 
a molecular model optimized with the commercial software SPARTAN26 by means of the program 122 
FOX27 with the parallel tempering algorithm. Some constraints were introduced to FOX, considering 123 
aromatic rings as rigid groups. Several trials of 20 million runs were performed. The refinement of the 124 
structure has been performed by the Rietveld method using FullProf;28 Figure 2 depicts the final 125 
Rietveld plot. The crystal structure of anhydrous form I has been solved at room temperature from single 126 
crystal X-ray diffraction (SXRD) in order to compare with form II since the structures deposited at the 127 
CSD29 have been solved at different temperatures. A summary of crystal data and relevant refinement 128 
parameters are given in Table 1. 129 
2.2.2. Differential Scanning Calorimetry (DSC). Differential scanning calorimetry analysis were carried 130 
out by means of a Mettler-Toledo DSC-822e calorimeter. Experimental conditions: aluminum crucibles 131 
of 40 μL volume, atmosphere of dry nitrogen with 50 mL/min flow rate, heating rate of 10 °C/min. The 132 
calorimeter was calibrated with indium of 99.99% purity (m.p.: 156.4 °C, ΔH: 28.55 J/g). 133 
2.2.3. Thermogravimetric Analysis (TGA). Thermogravimetric analyses were performed on a Mettler-134 
Toledo TGA-851e thermobalance. Experimental conditions: alumina crucibles of 70 μL volume, 135 
atmosphere of dry nitrogen with 50 mL/min flow rate, and heating rate of 10 °C/min. 136 
2.2.4. Dynamic Vapor Sorption (DVS). The water sorption and desorption processes were measured on 137 
a DVS-1000 instrument from Surface Measurement Systems. The samples were mounted on a balance 138 
and studied over a humidity range from 0% to 90% RH, and then decreased to 0% RH at 25 and 40 °C 139 
using a three-cycle method. The equilibrium condition for each step was set to a mass constancy of 140 
±0.001% over 60 min and a maximum time limit of 1440 min for each step. 141 
  142 
3. RESULTS AND DISCUSSION 143 
 144 
Sildenafil, the ingredient of Viagra, is the first oral drug used for the medical treatment of erectile 145 
dysfunction and has been recently used for the treatment of pulmonary hypertension30,31 but due to its 146 
low water solubility it is generally formulated as sildenafil citrate.32 The crystal structures of sildenafil 147 
base, sildenafil citrate monohydrate, and sildenafil saccharinate have been reported elsewhere.29 With 148 
the aim to study the solid state of this API, we conducted an extensive polymorph screening by using a 149 
broad set of thermodynamic and kinetic experimental conditions from a variety of 54 solvents,33 which 150 
produced 98 individual crystalline solids. Six new solvates (toluene, anisole, acetonitrile, propanenitrile, 151 
dioxane, and chloroform) and a new polymorph of sildenafil have been discovered, and their crystal 152 
structures were solved. The density functional theory (DFT) analysis of toluene, anisole, dioxane, and 153 
chloroform solvates is the subject of another research paper, in which the formation of an apparently 154 
innocent intramolecular H-bond has a remarkable influence on the solid state architecture of the 155 
sildenafil solvates.34 156 
During the polymorph screening with 53 out of 54 organic solvents only the known form I or new 157 
solvates (as mentioned before) were obtained except when acetonitrile was used. In particular, 158 
crystallizing or slurrying in this solvent produced three new solid forms depending on whether the solid 159 
obtained was extensively dried or not. When the solid obtained by slurrying sildenafil in acetonitrile was 160 
dried under a vacuum, an anhydrous new form (form II) was obtained, but if the solid was only filtered 161 
and directly analyzed without further drying, a new solvate (form ACNII) was produced with 2:1 162 
sildenafil/acetonitrile stoichiometry (deduced from TGA, Figure S10). Moreover, needles of a different 163 
acetonitrile solvate with 1:1 sildenafil/acetonitrile stoichiometry were obtained (solvate form ACNI) by 164 
slow evaporation of an acetonitrile solution of sildenafil at room temperature, and its crystal structure 165 
was solved by SXRD analysis. The PXRD diffractogram of solvate form ACNII was indexed (Figure 166 
S13) at room temperature, and its stoichiometry was deduced from TGA (Figure S10). The two solvates 167 
show a very similar PXRD diagram and cell parameters, which suggests that both solvates can be 168 
isostructural, Figure 3. See Supporting Information for further detail. 169 
The DSC of sildenafil form II shows two overlapped endothermic/exothermic phenomena prior to the 170 
melting of form I (Figure 4), while modulated DSC (Figure S8, Supporting Information) shows in the 171 
reversing signal an increase of heat capacity without melting followed by an exothermic broad peak in 172 
the nonreversing signal, suggesting that form II transforms into form I upon heating through a two-step 173 
process involving a glass-like solid. On the other hand, desolvation of solvate form ACNII by air drying 174 
at room temperature produced the new anhydrous form II, while DSC of solvate form ACNII showed a 175 
melting point, which is 5 °C lower than form I, probably due to lower crystallinity of the sample after 176 
desolvation and recrystallization (Figures 4, S9 and S10). The crystal structure of the new anhydrous 177 
form II was solved by means of direct space strategies from PXRD data, and the analysis of the crystal 178 
structures reveals that anhydrous form II is an isomorphic desolvate of the new acetonitrile solvate form 179 
ACNI. Figure 5 shows that the only significant difference between both forms is the more opened 180 
conformation of the propyl groups in the desolvate which cannot completely fill the voids left by the 181 
removed solvent. The fact that anhydrous form II has only been detected in 1 out of 54 solvents can 182 
explain why new anhydrous form II has not been previously reported in the literature and points out an 183 
important conclusion of this work as it will be discussed later. 184 
The crystal structures of the two anhydrous forms at room temperature have been compared, and a 185 
careful analysis of the packing reveals that the asymmetric unit independent molecules of both forms 186 
establish the same strong intramolecular hydrogen bond between the ethoxy oxygen and the pyrimidine 187 
nitrogen. Thus, the observed differences can be considered as conformational adjustments of the same 188 
gasphase conformer, according to the cutoff value proposed by Cruz-Cabeza and Bernstein in their 189 
analysis of conformational polymorphism35 since the root-mean-square distance (RMSD) value 190 
computed using Mercury is less than 0.375 Å. Among the observable conformational adjustments, the 191 
most relevant one involves the propyl groups, Figure 6. 192 
This can be better visualized through the fingerprint plots36,37 from Hirshfeld surfaces.38 Although the 193 
essential features of the intermolecular atom−atom contacts are very similar, in form II the H···H 194 
contacts (highlighted with a black circle in Figure 7) are much shorter than in form I as a consequence of 195 
the necessary folding of the propyl groups to maintain free the cavity previously occupied by the 196 
acetonitrile molecules in the solvate. In acetonitrile solvate ACNI the short H···H contacts were already 197 
present, and while anhydrous form I has a more extended configuration with less short H···H contacts 198 
the desolvate form II keeps much of the parent structure of the ACNI solvate, which explains why the 199 
short H···H contacts are also present in form II (see Tables 1 and 2 of Supporting Information). These 200 
interatomic contacts are presumably repulsive according to the accepted van der Waals diameter of the 201 
hydrogen atom (1.1−1.2 Å). However, only a small number of organic crystal structures have been 202 
reported with H···H interatomic distances lower than 2.2 Å,39 which are associated with repulsive 203 
forces to preserve the internal equilibrium in the crystal structure,40 as appears to be the case of 204 
anhydrous form II and solvate form ACNI. See Supporting Information for further detail. 205 
The most important consequence of anhydrous form II being an isomorphic desolvate of acetonitrile 206 
solvate is that there are bigger finite voids (rather than interconnected channels) than in form I. These 207 
have been calculated using the contact surface model using Mercury with a probe of 0,88 Å radius and 208 
shown in Figure 8. Since crystal structures of anhydrous form I and solvate ACNI have been solved at 209 
room temperature, there is disorder on the propyl groups (not present at 100 K, data not shown), which 210 
can be explained based on the fact that propyl groups do not establish strong intermolecular interactions 211 
with the surrounding atoms. This disorder is also probably present in anhydrous form II because the 212 
voids are bigger; however since the structure has been solved by direct space methods from PXRD, the 213 
disorder cannot be directly measured. 214 
On the other hand, the intermolecular contacts in both forms are very similar to hydrogen-bonded zigzag 215 
chains formed between the carbonylic oxygen and the aromatic protons. Moreover, the same self-216 
assembled dimers are formed through weak hydrogen bonds between the sulfoxide oxygens and ethyl 217 
groups, and finally the same stacked configuration between aromatic rings are also observed. However, 218 
an important packing difference is present as a consequence of a noncrystallographic inversion center in 219 
one of every three layers (highlighted in Figure 9) in form II with respect to form I. Thus, forms I and II 220 
can be considered morphotropic polymorphs since a noncrystallographic rearrangement transforms one 221 
form into the other.41 222 
In spite of the considerable research conducted with solvated drugs, the mechanisms that explain the 223 
solvate formation are still unclear. However, two different mechanisms (or a combination of both) in 224 
which solvent molecules incorporate into the crystal lattice have been postulated: solvent molecules can 225 
provide extra intermolecular interactions (a) and/or they help to decrease voids in the crystal (b).42 In 226 
order to assess the stability of the less dense anhydrous form II, the potential to absorb water and 227 
acetonitrile of both anhydrous forms has been tested. DVS experiments have been performed, and they 228 
show that form I only absorbs 0.23 and 0.73% moisture at 25 and 40 °C respectively, while form II 229 
absorbs 4.64 and 1.36% moisture at 25 °C (Figure 10) and 40 °C respectively (see Supporting 230 
Information for further detail). The fact that form II absorbs more water than form I when exposed to 231 
high relative humidity can be due to the presence of bigger voids in form II that attract more water by 232 
capillary condensation. The formation of new hydrates has not been detected by PXRD analysis of the 233 
resulting samples after the DVS experiments. Moreover, a low percentage of form I was detected in the 234 
sample which was initially form II, which suggests a water-assisted phase transition, as has been shown 235 
for paracetamol.43 236 
On the other hand, when exposed to acetonitrile vapors, both anhydrous forms convert into solvate form 237 
ACNII but not to solvate form ACNI, which suggests that the 1:1 acetonitrile solvate is formed through 238 
a dissolution/recrystallization process, while the 2:1 acetonitrile solvate is formed by solvent diffusion. 239 
Finally, a new propanenitrile solvate was discovered during the solid forms screening. Interestingly, 240 
although acetonitrile and propanenitrile only differ in one methylene group, the crystal structures of both 241 
solvates are dramatically different, with the structure of the propanenitrile solvate resembling that of 242 
anhydrous form I (Figure 11). Desolvation under a vacuum of the propanenitrile solvate produced 243 
anhydrous form I, an expected outcome due to the packing similarity between both forms. 244 
 245 
 246 
 247 
248 
4. CONCLUSION 249 
 250 
In summary, we have discovered a new anhydrous form of sildenafil (form II) which is a desolvate of a 251 
new 1:1 acetonitrile solvate. Both anydrous forms are morphotropically related, and the presence of 252 
voids in form II are created by desolvation of the acetonitrile solvate. Although 54 organic solvents have 253 
been tested during the solid forms, screening the new polymorph is only obtained when acetonitrile is 254 
used. Thus, this study highlights the importance of intensive solvate screening during early stages of a 255 
polymorph/cocrystal screen of APIs because some solvates can be precursors and provide the key to the 256 
discovery of potential metastable polymorphs that otherwise would remain unknown. 257 
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Legends to figures 377 
 378 
Figure. 1. Molecular structure of sildenafil. 379 
 380 
Figure. 2 Final Rietveld plot for the crystal structure refinement of sildenafil form II. Agreement 381 
factors: Rwp = 12.3%, Chi2 = 4.93. The plot shows the experimental PXRD profile (red marks), the 382 
calculated PXRD profile (black solid line), and the difference profile (blue, lower line). Tick marks 383 
indicate peak positions. 384 
 385 
Figure. 3 PXRD diagrams of acetonitrile solvates form I (simulated from crystal structure) and II. 386 
 387 
Figure. 4 DSC thermograms of anhydrous forms I (mp onset: 189°C; enthalpy: 87.1 J/g) and II (mp 388 
onset: 188 °C; enthalpy: 92.4 J/g)and solvate form ACNII (mp onset: 184 °C; enthalpy: 75.6 J/g) of 389 
sildenafil. 390 
 391 
Figure. 5 Crystal structures of anhydrous form II and ACN solvate form ACNI. 392 
 393 
Figure. 6 Overlap of sildenafil molecules of anhydrous forms I (blue) and II (red). The computed 394 
RMSD is 0.338 Å. 395 
 396 
Figure. 7 Fingerprint plots computed from Hirshfeld surfaces of form I (left) and form II (right). Strong 397 
H···O contacts are highlighted in red and H···H contacts in black. 398 
 399 
Figure. 8 Calculated voids of anhydrous forms of sildenafil. 400 
  401 
Figure. 9 Packing in the b axis direction showing the layer involved in a noncrystallographic inversion 402 
center. 403 
 404 
Figure. 10 Dynamic vapor sorption isotherms of form I (a) and form II (b) at 25 °C. 405 
 406 
Figure. 11 Crystal structures of anhydrous form I, propanenitrile solvate, anhydrous form II, and 407 
acetonitrile solvate form ACNI. 408 
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Table 1 Crystal Data and Structure Refinement Parameters for the Different Forms of Sildenafil 471 
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